BRF
CTSO icon

B. Riley Financial’s Cytosorbents Corp CTSO Stock Holding History

B. Riley Financial’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-152,620
Closed -$992K – 299
2017
Q4 		$992K Buy
+152,620
New +$971K 0.26% 99

Other funds holding CTSO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

B. Riley Financial's CTSO Position: Q1 2018 in Review

B. Riley Financial sold out of Cytosorbents Corp (CTSO) in Q1 2018, closing a stake of 152,620 shares — an estimated $992K sold.

B. Riley Financial first reported a position in CTSO in Q4 2017 and held it in 1 quarter. The position peaked at $992K in Q4 2017. 49 funds tracked by Wall St. Rank hold CTSO as of Q1 2018.

  • B. Riley Financial reported no remaining Cytosorbents Corp position as of Q1 2018 after selling out during the quarter.
  • B. Riley Financial sold 152,620 Cytosorbents Corp shares in Q1 2018, an estimated $992K.
  • B. Riley Financial first reported a position in Cytosorbents Corp in Q4 2017 and held it in 1 quarter.
  • B. Riley Financial's Cytosorbents Corp position peaked at $992K in Q4 2017.
  • 49 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2018.

Based on B. Riley Financial's 13F filing for Q1 2018, filed 4 May 2018.